Monte Rosa Therapeutics Announces Phase 1 Study of NEK7 Degrader MRT-8102 for Cardiovascular Diseases
Reuters
Nov 10
<a href="https://laohu8.com/S/GLUE">Monte Rosa Therapeutics</a> Announces Phase 1 Study of NEK7 Degrader MRT-8102 for Cardiovascular Diseases
Monte Rosa Therapeutics Inc. announced that it will present preclinical data on MRT-8102, a NEK7-directed molecular glue degrader, at the American Heart Association's Scientific Sessions 2025 in New Orleans. MRT-8102 is being developed as a potential treatment for inflammatory diseases driven by the NLRP3 inflammasome, including cardiovascular and cardiometabolic diseases such as pericarditis and atherosclerosis. The company reported that MRT-8102 selectively degrades NEK7, leading to inhibition of the NLRP3 inflammasome and reduced production of multiple inflammatory cytokines in both in vitro and in vivo models. Initial data from an ongoing Phase 1 study of MRT-8102 in healthy volunteers and subjects with elevated cardiovascular disease risk are expected in the first half of 2026. The preclinical findings will be presented in a poster session on November 8, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9571686-en) on November 08, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.